VasoDynamics receives PING Innovation Award 2025
VasoDynamics awarded the Innovation of the Year 2025 by the Pharmaceutical Industry Network Group (PING) after its successful clinical trial showing prevention of severe oral mucositis induced by radiotherapy in patients with head and neck cancers.
12th May 2025
The 16th Annual Pharmaceutical Industry Network Group (PING) conference, hosted by the law firm VWV and sponsored by Hertfordshire Futures, announced VasoDynamics Ltd as the winner of the PING Innovation Award of 2025. We are extremely proud to have received this award in recognition of our innovation efforts and of the successful completion of our NG11-2 Phase Ib trial for the prevention of radiotherapy-induced severe oral mucositis in patients with head and neck cancers.
Photo Credit – Stevenage Bioscience Catalyst
Dr Ningfeng Fiona Li, CEO of VasoDynamics, said:
“We are deeply honoured to have received this recognition from our local life science and pharmaceutical community. We innovate not just as clinical doctors, scientists and professionals, but as children, friends and family of people whose lives have been impacted by cancer, with the desire to support our patients and loved ones. We choose to focus on preventing the side-effects of cancer treatments, because we believe that dealing with difficult diseases, such as cancer, is no different from fighting on the battlefield – we shall be equipped with protective shields as well as sharp swords!
The award reflects the collective effort of our incredible team, supportive mentors and partners, and the extremely supportive local community. Thank you to the PING Award Committee for the acknowledgement of our work, this motivates us to keep challenging the status quo and move forward towards the next breakthrough.”
For enquiries, please contact:
Dr Ningfeng Fiona Li, CEO
fiona.li@vasodynamics.co.uk
Notes to Editors:
About VasoDynamics
VasoDynamics is a pharmaceutical development company based in Stevenage-London, UK. It is a clinical stage biopharma company with experienced and culture-diversified executives who have shared vision to improve the standard of cancer care globally. Recognising the mounting cost pressures facing healthcare payers all over the world, the company is developing a number of cost-effective medicines, all of which target the prevention of debilitating and often dose-limiting complications of cancer therapy, such as chemotherapy and radiotherapy induced mucositis, dermatitis, and hair-loss. We take great pride in our culture of scientific and development rigour, and our programmes are based on scientific finding and innovations from world-leading research bodies. The company’s proprietary technology platform utilises the different dynamics of normal and cancerous vasculatures developing a serials of pipeline products for various types of cancer patient cohorts, hence to achieve the most effective and patient friendly protections to prevent severe side-effects during various types of cancer treatments.